Shares of ConforMIS, Inc. (NASDAQ:CFMS) gapped down prior to trading on Friday following insider selling activity. The stock had previously closed at $6.46, but opened at $5.93. ConforMIS shares last traded at $5.99, with a volume of 1,035,494 shares.

Specifically, Director Philipp Lang sold 74,876 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $8.00, for a total transaction of $599,008.00. Following the completion of the transaction, the director now owns 589,495 shares of the company’s stock, valued at $4,715,960. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Cerveny sold 3,569 shares of the stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $8.59, for a total value of $30,657.71. Following the transaction, the insider now directly owns 87,501 shares of the company’s stock, valued at approximately $751,633.59. The disclosure for this sale can be found here. Insiders have sold 877,058 shares of company stock valued at $7,421,366 in the last three months. Insiders own 9.20% of the company’s stock.

A number of research firms have recently issued reports on CFMS. B. Riley restated a “buy” rating and issued a $13.00 price target on shares of ConforMIS in a research report on Friday, November 4th. Oppenheimer Holdings, Inc. set a $13.00 price target on ConforMIS and gave the company a “buy” rating in a research report on Monday, October 24th. Zacks Investment Research upgraded ConforMIS from a “hold” rating to a “buy” rating and set a $9.50 price target for the company in a research report on Tuesday, November 8th. Canaccord Genuity set a $12.00 price target on ConforMIS and gave the company a “buy” rating in a research report on Monday, January 23rd. Finally, J P Morgan Chase & Co restated a “hold” rating and issued a $11.00 price target on shares of ConforMIS in a research report on Friday, November 4th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. ConforMIS currently has a consensus rating of “Buy” and an average target price of $10.61.

The company’s market capitalization is $256.44 million. The stock’s 50 day moving average price is $8.31 and its 200-day moving average price is $8.59.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, February 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.07. ConforMIS had a negative return on equity of 46.41% and a negative net margin of 73.53%. The company had revenue of $21.70 million for the quarter, compared to analysts’ expectations of $21.37 million. Equities research analysts predict that ConforMIS, Inc. will post ($1.34) EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Papp L Roy & Associates acquired a new stake in shares of ConforMIS during the third quarter worth $106,000. Trent Capital Management Inc. NC acquired a new stake in shares of ConforMIS during the fourth quarter worth $177,000. A.R.T. Advisors LLC acquired a new stake in shares of ConforMIS during the fourth quarter worth $178,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of ConforMIS during the second quarter worth $204,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of ConforMIS during the fourth quarter worth $311,000. 39.63% of the stock is currently owned by hedge funds and other institutional investors.

“ConforMIS, Inc. (CFMS) Shares Gap Down Following Insider Selling” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The correct version of this piece can be viewed at http://www.dailypolitical.com/2017/02/17/conformis-inc-cfms-shares-gap-down-following-insider-selling-2.html.

About ConforMIS

ConforMIS, Inc is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee.

5 Day Chart for NASDAQ:CFMS

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.